Advisory board
Our advisory board brings together leading experts in immunology, oncology, and clinical development. They guide our scientific strategy and ensure that our therapeutic programs align with patient needs and regulatory best practices.
Clinical programs
We run state-of-the-art clinical research programs, from early-stage proof-of-concept studies to full clinical trials. Our goal is to bring novel anti-APC therapeutics from discovery to patients as safely and efficiently as possible.
Research & Development
Discovery: Identifying and validating novel APC targets Preclinical Development: In vitro and in vivo testing to assess safety and efficacy Translational Science: Biomarker development, mechanism-of-action studies, and tailored therapeutic designs
Partnerships
We collaborate with pharmaceutical companies, academic institutions, and biotechnology innovators to co-develop therapies, share knowledge, and accelerate development timelines.
